Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 1/20 | 0.57 |
| ▸ | MCL1 | Q07820 | 8/20 | 0.54 |
| ▸ | BCL2 | P10415 | 3/20 | 0.54 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.49 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6099158 | 0.91 | BCL2 (0.55) | MCL1BCL2SRD5A2MAOB | |
| SCHEMBL8303038 | 0.83 | MCL1 (0.57) | MCL1BCL2 | |
| SCHEMBL19149410 | 0.82 | HTR7 (0.60) | HTR7MCL1BCL2MCHR1SRD5A2 | |
| SCHEMBL19172461 | 0.82 | HTR7 (0.65) | HTR7MCL1BCL2MCHR1SRD5A2 | |
| SCHEMBL27619992 | 0.80 | MCL1 (0.55) | MCL1BCL2SRD5A2 | |
| SCHEMBL6724557 | 0.79 | MTNR1A (0.46) | MCL1BCL2 | |
| SCHEMBL23927885 | 0.79 | HTR2A (0.66) | HTR7MCL1BCL2MCHR1 | |
| SCHEMBL8163392 | 0.77 | MAPK1 (0.60) | — | |
| SCHEMBL6089283 | 0.76 | HTR7 (0.55) | HTR7MCL1BCL2MCHR1SRD5A2 | |
| SCHEMBL6089075 | 0.76 | HTR7 (0.55) | HTR7MCL1BCL2MCHR1SRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040214832-A1 | Piperazine derivative renin inhibitors | WARNER-LAMBERT COMPANY LLC | 2004-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214832-A1 | Piperazine derivative renin inhibitors | REN, ACE, AGTR2 | HTR7 1644/4885MCL1 4645/4885BCL2 4317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.